keyword
MENU ▼
Read by QxMD icon Read
search

Hepatology

keyword
https://www.readbyqxmd.com/read/29922763/gastrointestinal-endoscopy-in-patients-on-direct-oral-anticoagulants-a-consensus-paper-of-the-romanian-society-of-gastroenterology-and-hepatology
#1
Andreea Farcas, Simona Bataga, Cristina Cijevschi, Mircea Diculescu, Daniela Dobru, Eugen Dumitru, Adrian Goldis, Laurentiu Nedelcu, Alina Popescu, Ioan Sporea, Anca Trifan, Simona Valean, Cristian Gheorghe, Dan Lucian Dumitrascu
Management of patients undergoing endoscopy and under treatment with the newer direct oral anticoagulants (DOACs) is a common and a complex clinical issue that gastroenterologists have to face more and more often these days. The increasing use of DOACs in patients requiring both short- and long-term anticoagulation is mostly due to the advantages these agents offer, among which the lack of monitoring requirements and the reduced need of dose adjustments are perhaps the most important ones. Managing these patients in the peri-endoscopic period implies balancing the risk for thrombosis that a certain patient carries and the bleeding risk associated with the endoscopic procedure itself...
June 2018: Journal of Gastrointestinal and Liver Diseases: JGLD
https://www.readbyqxmd.com/read/29916949/central-line-in-long-term-parenteral-nutrition-in-children-a-european-survey
#2
Iva Hojsak, Florence Lacaille, Girish L Gupte, Jutta Köglmeier
BACKGROUND AND AIMS: The guidelines for the insertion and maintenance of the central venous catheter (CVC) in children on long-term parenteral nutrition (PN) were published 12 years ago and studies evaluating the outcomes are limited. Therefore, the aim of this study was to perform a survey about criteria for CVC insertion and maintenance in intestinal failure/rehabilitation centres treating children on home PN. METHODS: An on-line cross-sectional survey based on previous European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) PN guidelines was distributed electronically to the members of the ESPGHAN networking group, Network for Intestinal Failure and Transplantation in Europe (NITE) and tertiary paediatric gastroenterology centres in Europe...
June 18, 2018: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/29916948/prospective-evaluation-of-the-espghan-guidelines-for-diagnosis-of-coeliac-disease-in-new-zealand-children
#3
Jonathan Bishop, Peter Reed, Paul Austin, Miriam Hurst, Rohan Ameratunga, Alyson Craigie, Jeannette McFarlane, Simon E Chin, Stephen M Mouat, Helen M Evans
OBJECTIVE: The 2012 European Society of Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) guideline for diagnosis of celiac disease (CD) questioned the requirement for intestinal biopsy to confirm the diagnosis. The guideline recommends that, in symptomatic patients with consistent HLA subtypes, the diagnostic accuracy of strongly positive serology is sufficient to confirm the diagnosis. We prospectively assessed these guidelines in a "real-life" clinical setting...
June 18, 2018: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/29912922/impact-of-pre-sarcopenia-in-sorafenib-treatment-for-advanced-hepatocellular-carcinoma
#4
Hitomi Takada, Masayuki Kurosaki, Hiroyuki Nakanishi, Yuka Takahashi, Jun Itakura, Kaoru Tsuchiya, Yutaka Yasui, Nobuharu Tamaki, Kenta Takaura, Yasuyuki Komiyama, Mayu Higuchi, Youhei Kubota, Wann Wang, Mao Okada, Nobuyuki Enomoto, Namiki Izumi
BACKGROUND: The present study aimed to investigate the impact of pre-sarcopenia on the prognosis of patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. METHODS: We enrolled 214 patients (71 ± 10 years old; 166 men and 48 women; 90% Child-Pugh grade A and 10% Child-Pugh grade B) treated with sorafenib in our hospital from July 2009 to August 2016. The muscle volume was measured from CT images just before sorafenib administration using software (SliceOmatic)...
2018: PloS One
https://www.readbyqxmd.com/read/29910011/misconceptions-preferences-and-barriers-to-alcohol-use-disorder-treatment-in-alcohol-related-cirrhosis
#5
Jessica L Mellinger, G Scott Winder, Melissa DeJonckheere, Robert J Fontana, Michael L Volk, Anna S F Lok, Frederic C Blow
BACKGROUND: While alcohol cessation improves mortality in alcoholic liver disease (ALD), many patients struggle to achieve abstinence. Our aim was to characterize ALD patients' preferences, misconceptions, and barriers to alcohol use treatment options. METHODS: This mixed-methods study included outpatients with a history of alcohol-related cirrhosis or alcoholic hepatitis recruited from a hepatology clinic for a survey or an in-depth semi-structured interview. We purposefully sampled men and women, compensated and decompensated patients to ensure adequate representation of gender and severity of liver disease for the qualitative interviews...
August 2018: Journal of Substance Abuse Treatment
https://www.readbyqxmd.com/read/29901556/universal-recommendations-for-the-management-of-acute-diarrhea-in-non-malnourished-children
#6
Alfredo Guarino, Andrea Lo Vecchio, Jorge Amil Dias, James A Berkley, Chris Boey, Dario Bruzzese, Mitchell B Cohen, Sylvia Cruchet, Ilaria Liguoro, Eduardo Salazar-Lindo, Bhupinder Sandhu, Philip M Sherman, Toshiaki Shimizu
OBJECTIVES: Despite a substantial consistency in recommendations for the management of children with acute gastroenteritis (AGE), a high variability in clinical practice and a high rate of inappropriate medical interventions persist in both developing and developed countries.Aim of this study was to develop a set of clinical recommendations for the management of non-severely malnourished children with AGE to be applied worldwide. METHODS: The Federation of International Societies of Pediatric Gastroenterology, Hepatology, and Nutrition (FISPGHAN) Working Group (WG) selected care protocols on the management of acute diarrhea in infants and children aged between 1 month and 18 years...
June 12, 2018: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/29895448/risk-factors-for-acquiring-hcv-at-a-healthcare-center-in-hidalgo-mexico
#7
R Contreras-Omaña, F J García-Lemus, A García-Camacho
INTRODUCTION AND AIMS: The approach to HCV infection begins with the directed search for risk factors linked to its acquisition. Therefore, our primary aim was to identify the prevalence of risk factors associated with HCV infections in insured individuals seen at the Hidalgo delegation of the IMSS. MATERIALS AND METHODS: An observational, descriptive, cross-sectional study was conducted through validated surveys that identified major and minor risk factors. In cases of major risk factors, the Advanced Quality™ RAPID-ANTI-HCV TEST Accutrack® tests were applied to detect anti-HCV...
June 9, 2018: Revista de Gastroenterología de México
https://www.readbyqxmd.com/read/29894288/renovation-of-annals-of-hepatology-s-scientific-scope-towards-preventing-rather-than-treating-end-stage-liver-disease
#8
Arturo Panduro, Claudio Tiribelli, Norberto C Chávez-Tapia, Marco Arrese, Misael Uribe
No abstract text is available yet for this article.
July 2018: Annals of Hepatology
https://www.readbyqxmd.com/read/29893235/non-alcoholic-fatty-liver-disease-and-the-interface-between-primary-and-secondary-care
#9
REVIEW
Emmanuel A Tsochatzis, Philip N Newsome
Non-alcoholic fatty liver disease (NAFLD) has a prevalence of 25-30% in unselected populations and has become the main reason for referrals to hepatology services. From the perspective of liver disease, NAFLD has a high prevalence but low severity. Screening studies in people at risk for NAFLD have shown a prevalence of advanced fibrosis of 5%, which underlines the need for robust pathways for risk stratification in primary care, with subsequent referrals as required. In this Review, we discuss the interface between primary and secondary care with regards to risk stratification and management of patients with NAFLD...
July 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29893228/scoping-the-problem-endoscopy-associated-infections
#10
EDITORIAL
The Lancet Gastroenterology Hepatology
No abstract text is available yet for this article.
July 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29888828/durability-of-virologic-response-risk-of-de-novo-hepatocellular-carcinoma-liver-function-and-stiffness-two-years-after-treatment-with-ombitasvir-paritaprevir-ritonavir-%C3%A2-dasabuvir-%C3%A2-ribavirin-in-the-amber-real-world-experience-study
#11
Robert Flisiak, Ewa Janczewska, Mariusz Łucejko, Ewa Karpińska, Dorota Zarębska-Michaluk, Khalil Nazzal, Beata Bolewska, Jolanta Białkowska, Hanna Berak, Katarzyna Fleischer-Stępniewska, Krzysztof Tomasiewicz, Kornelia Karwowska, Krzysztof Simon, Anna Piekarska, Olga Tronina, Ewelina Tuchendler, Aleksander Garlicki
We followed for 2 years patients treated with Direct Acting Agents (DAA) to assess long-term durability of virologic response, improvement of liver function, reduction of liver stiffness (LS), and risk of hepatocellular carcinoma (HCC).The study included patients from 16 hepatologic centers involved in the AMBER, investigators initiated study on treatment of chronic hepatitis C patients within a programme preceding EU registration of Ombitasvir/Paritaprevir/ritonavir±Dasabuvir±Ribavirin. A total of 204 patients among 209 from the primary study were enrolled; 200 with available testing at 2 years follow-up (2yFU) with undetectable HCV RNA (198 responders and 2 non-responders retreated)...
June 11, 2018: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29881825/metabolic-risk-factors-are-associated-with-non-hepatitis-b-non-hepatitis-c-hepatocellular-carcinoma-in-taiwan-an-endemic-area-of-chronic-hepatitis-b
#12
Shiu-Feng Huang, Il-Chi Chang, Chih-Chen Hong, Tseng-Chang Yen, Chao-Long Chen, Cheng-Chung Wu, Cheng-Chung Tsai, Ming-Chih Ho, Wei-Chen Lee, Hsien-Chung Yu, Ying-Ying Shen, Hock-Liew Eng, John Wang, Hui-Hwa Tseng, Yung-Ming Jeng, Chau-Ting Yeh, Chi-Ling Chen, Pei-Jer Chen, Yun-Fan Liaw
Metabolic risk factors, such as obesity, fatty liver, high lipidemia, and diabetes mellitus are associated with increased risk for nonviral hepatocellular carcinoma (HCC); however, few nonviral HCC studies have stratified patients according to underlying etiologies. From 2005 to 2011, 3,843 patients with HCC were recruited into the Taiwan Liver Cancer Network. Of these patients, 411 (10.69%) who were negative for hepatitis B virus (HBV), surface antigen, HBV DNA, and anti-hepatitis C virus (HCV) antibody were classified as non-HBV non-HCV (NBNC)-HCC...
June 2018: Hepatology Communications
https://www.readbyqxmd.com/read/29881824/inhibition-of-insulin-like-growth-factor-1-receptor-enhances-the-efficacy-of-sorafenib-in-inhibiting-hepatocellular-carcinoma-cell-growth-and-survival
#13
Fang Wang, Thomas Bank, Gregory Malnassy, Maribel Arteaga, Na Shang, Annika Dalheim, Xianzhong Ding, Scott J Cotler, Mitchell F Denning, Michael I Nishimura, Peter Breslin, Wei Qiu
Hepatocellular carcinoma (HCC) is the fifth most common primary cancer and second largest cause of cancer-related death worldwide. The first-line oral chemotherapeutic agent sorafenib only increases survival in patients with advanced HCC by less than 3 months. Most patients with advanced HCC have shown limited response rates and survival benefits with sorafenib. Although sorafenib is an inhibitor of multiple kinases, including serine/threonine-protein kinase c-Raf, serine/threonine-protein kinase B-Raf, vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3, and platelet-derived growth factor receptor β, HCC cells are able to escape from sorafenib treatment using other pathways that the drug insufficiently inhibits...
June 2018: Hepatology Communications
https://www.readbyqxmd.com/read/29881823/telomerase-reverse-transcriptase-mutations-in-plasma-dna-in-patients-with-hepatocellular-carcinoma-or-cirrhosis-prevalence-and-risk-factors
#14
Jingjing Jiao, Gordon P Watt, Heather L Stevenson, Tiffany L Calderone, Susan P Fisher-Hoch, Yuanqing Ye, Xifeng Wu, John M Vierling, Laura Beretta
Telomerase reverse transcriptase ( TERT ) mutation is the most frequent genetic alteration in hepatocellular carcinoma (HCC). Our aims were to investigate whether TERT mutations can be detected in circulating cell-free DNA (cfDNA) of patients with HCC and/or cirrhosis and characterize clinical parameters associated with these mutations. We retrieved data on TERT C228T and C250T promoter mutations in 196 HCCs from The Cancer Genome Atlas. We measured these TERT mutations in plasma cfDNA in 218 patients with HCC and 81 patients with cirrhosis without imaging evidence of HCC...
June 2018: Hepatology Communications
https://www.readbyqxmd.com/read/29881822/neutrophils-alleviate-fibrosis-in-the-ccl-4-induced-mouse-chronic-liver-injury-model
#15
Eiko Saijou, Yutaka Enomoto, Michitaka Matsuda, Cindy Yuet-Yin Kok, Shizuo Akira, Minoru Tanaka, Atsushi Miyajima
Tribbles pseudokinase 1 ( Trib1 ) is a negative regulator of CCAAT/enhancer binding protein α (C/EBPα) and is known to induce granulopoiesis while suppressing monocyte differentiation. Loss of Trib1 was previously shown to increase the neutrophil population in the spleen but lead to M2-like macrophage reduction. Because M2 macrophages are anti-inflammatory and promote tissue repair by producing fibrogenic factors, we investigated liver fibrosis in Trib1 -deficient mice. Interestingly, loss of Trib1 suppressed fibrosis in the CCl4 -induced chronic liver injury model...
June 2018: Hepatology Communications
https://www.readbyqxmd.com/read/29881821/age-dependent-glycosylation-of-the-sodium-taurocholate-cotransporter-polypeptide-from-fetal-to-adult-human-livers
#16
Camillo Sargiacomo, Hoda El-Kehdy, Guillaume Pourcher, Bruno Stieger, Mustapha Najimi, Etienne Sokal
Sodium taurocholate cotransporter polypeptide (NTCP), mainly expressed on the sinusoidal membrane of hepatocytes, is one of the major transporters responsible for liver bile acid (BA) re-uptake. NTCP transports conjugated BA from the blood into hepatocytes and is crucial for correct enterohepatic circulation. Studies have shown that insufficient hepatic clearance of BA correlates with elevated serum BA in infants younger than 1 year of age. In the current study, we investigated human NTCP messenger RNA and protein expression by using reverse-transcription quantitative polymerase chain reaction and immunoblotting in isolated and cryopreserved human hepatocytes from two different age groups, below and above 1 year of age...
June 2018: Hepatology Communications
https://www.readbyqxmd.com/read/29881820/clinical-application-of-the-globe-and-united-kingdom-primary-biliary-cholangitis-risk-scores-in-a-trial-cohort-of-patients-with-primary-biliary-cholangitis
#17
Marco Carbone, Maren H Harms, Willem J Lammers, Tonya Marmon, Richard Pencek, Leigh MacConell, David Shapiro, David E Jones, George F Mells, Bettina E Hansen
The GLOBAL Primary Biliary Cholangitis (PBC) Study Group and United Kingdom-PBC (UK-PBC) Consortium have demonstrated that dichotomous response criteria are not as accurate as continuous equations at predicting mortality or liver transplantation in PBC. The aim of this analysis was to assess the clinical utility of the GLOBE and UK-PBC risk scores using data from POISE, a phase 3 trial investigating obeticholic acid (OCA) in patients with PBC. Data (N = 216) at baseline and month 12 were used to calculate the GLOBE and UK-PBC risk scores to assess the projected change in risk with OCA versus placebo...
June 2018: Hepatology Communications
https://www.readbyqxmd.com/read/29881819/external-validation-of-the-united-kingdom-primary-biliary-cholangitis-risk-scores-of-patients-with-primary-biliary-cholangitis-treated-with-ursodeoxycholic-acid
#18
Angela C Cheung, Aliya F Gulamhusein, Brian D Juran, Erik M Schlicht, Bryan M McCauley, Mariza de Andrade, Elizabeth J Atkinson, Konstantinos N Lazaridis
The United Kingdom-Primary Biliary Cholangitis (UK-PBC) risk scores are a set of prognostic models that estimate the risk of end-stage liver disease in patients with PBC at 5-, 10- and 15-year intervals. They have not been externally validated outside the United Kingdom. In this retrospective, external validation study, data were abstracted from outpatient charts and discrimination and calibration of the UK-PBC risk scores were assessed. A total of 464 patients with PBC treated with ursodeoxycholic acid were included...
June 2018: Hepatology Communications
https://www.readbyqxmd.com/read/29881818/protein-phosphatase-1-regulatory-subunit-3b-gene-variation-protects-against-hepatic-fat-accumulation-and-fibrosis-in-individuals-at-high-risk-of-nonalcoholic-fatty-liver-disease
#19
Paola Dongiovanni, Marica Meroni, Rosellina M Mancina, Guido Baselli, Raffaela Rametta, Serena Pelusi, Ville Männistö, Anna L Fracanzani, Sara Badiali, Luca Miele, Stefania Grimaudo, Salvatore Petta, Elisabetta Bugianesi, Giorgio Soardo, Silvia Fargion, Jussi Pihlajamäki, Stefano Romeo, Luca Valenti
Nonalcoholic fatty liver disease (NAFLD) is a major cause of liver damage and has a strong genetic component. The rs4841132 G>A variant, modulating the expression of protein phosphatase 1 regulatory subunit 3B ( PPP1R3B ), which is involved in glycogen synthesis, has been reported to reduce the risk of NAFLD but at the same time may favor liver disease by facilitating glycogen accumulation. The aim of this study was to assess the impact of rs4841132 on development of histologic steatosis and fibrosis in 1,388 European individuals in a liver biopsy cohort, on NAFLD hepatocellular carcinoma in a cross-sectional Italian cohort (n = 132 cases), and on liver disease at the population level in the United Kingdom Biobank cohort...
June 2018: Hepatology Communications
https://www.readbyqxmd.com/read/29881817/metastasis-associated-lung-adenocarcinoma-transcript-1-as-a-common-molecular-driver-in-the-pathogenesis-of-nonalcoholic-steatohepatitis-and-chronic-immune-mediated-liver-damage
#20
Silvia Sookoian, Diego Flichman, Martin E Garaycoechea, Julio San Martino, Gustavo O Castaño, Carlos J Pirola
Long noncoding RNAs (lncRNAs) are functional molecules that orchestrate gene expression. To identify lncRNAs involved in nonalcoholic fatty liver disease (NAFLD) severity, we performed a multiscale study that included: (a) systems biology modeling that indicated metastasis-associated lung adenocarcinoma transcript 1 ( MALAT1 ) as a candidate lncRNA for exploring disease-related associations, (b) translational exploration in the clinical setting, and (c) mechanistic modeling. MALAT1 liver profiling was performed in three consecutive phases, including an exploratory stage (liver samples from patients with NAFLD who were morbidly obese [n = 47] and from 13 individuals with normal liver histology); a replication stage (patients with NAFLD and metabolic syndrome [n =49]); and a hypothesis-driven stage (patients with chronic hepatitis C and autoimmune liver diseases, [n = 65])...
June 2018: Hepatology Communications
keyword
keyword
236
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"